ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Kamada (KMDA.TA)
Kamada stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Tel Aviv Stock Exchange · Israel
₪24.07▲ +0.42%
Prices as of Oct 26, 2026 · ILS
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Kamada in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Kamada
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Kamada a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₪22.66 and ₪25.60; in 9 out of 10, between ₪20.33 and ₪28.53. Estimated annual volatility is 37%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₪141B
- Market cap (USD)
- $45.5B
- P/E ratio
- 20.1
- Dividend yield
- 8.70%
- 52-week high
- ₪28.90
- 52-week low
- ₪19.56
- Revenue (12 months)
- $180M
- Operating margin
- 17.3%
- Net margin
- 11.6%
- Beta
- 0.13
What this means
ATLAS does not publish a fair value for KMDA.TA right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks KMDA.TA has traded between ₪19.56 and ₪28.90. Today it is 16.7% below that high and 23% above its low.
On the business: net margin is 11.6%; it trades at 20.1 times earnings.
Its beta is 0.13: it tends to move less than the market.
About the company
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics.
Want to see everything about Kamada?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Kamada do?
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapeutics.
What is the chance KMDA.TA goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, KMDA.TA ends the month between ₪22.66 and ₪25.60.
How big is Kamada and what is its P/E ratio?
Kamada's market capitalization is ₪141B. Its price-to-earnings (P/E) ratio is 20.1: you pay ₪20.1 for each ₪1.00 of yearly earnings.
Does Kamada pay a dividend?
Yes. KMDA.TA's current dividend yield is 8.70% at today's price (₪24.07).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer